ERBB2 and benign neoplasm: Out of 170 patients, 132 patients had a malignant breast tumor (78%) and 38 patients had a benign tumor (22%); 11 patients were classified as triple negative (6%), 22 as HER2 positive (13%), and 14 as luminal A (9%) vs. 81 as luminal B (81%).